Chemours (CC) PT Lowered to $20 at Jefferies
Jefferies analyst Laurence Alexander lowered the price target on Chemours (NYSE: CC) to $20.00 (from $21.00) while maintaining a Hold rating.
The analyst comments "Q4 EBITDA of $179 was $14m above both consensus and our estimate. 2025 EBITDA is pegged at $825-$975m (consensus $930m), with a QoQ decline in Q1. A decline in Chinese competitive pressure likely will be a TiO2 tailwind in Europe, and construction demand could strengthen in 2H25-2026. Opteon adoption will also provide some volume growth, amplified by productivity, offsetting soft Freon sales and weakness in APM."